Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 14/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 14/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 14/20 | 0.67 |
| ▸ | F10 | P00742 | 12/20 | 0.67 |
| ▸ | F9 | P00740 | 5/20 | 0.60 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093121 | 0.93 | F2 (0.66) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7091736 | 0.89 | F2 (0.68) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6742753 | 0.87 | F2 (0.68) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6737998 | 0.87 | KLKB1 (0.68) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7091734 | 0.86 | F2 (0.67) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6740053 | 0.86 | F10 (0.51) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7084382 | 0.85 | F2 (0.67) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6743095 | 0.85 | F10 (0.51) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6743079 | 0.84 | KLKB1 (0.53) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6742706 | 0.83 | F10 (0.53) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | claimed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | claimed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | claimed |
| US-6689770-B2 | AN INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | disclosed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | F12, F11, TFPI | F2 13/4885PRSS1 26/4885PRSS2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.